Square Pharma posts Tk600cr profit in July-Sept

During the first quarter of this fiscal, its gross revenue also grew by 15% to Tk2,161 crore compared to the previous fiscal year in the same quarter.

Square Pharmaceuticals Limited has reported a 9% growth in profit, amounting to Tk600 crore, in the July-September quarter of the fiscal year 2023-24.

During the first quarter of this fiscal, its gross revenue also grew by 15% to Tk2,161 crore compared to the previous fiscal year in the same quarter.

According to the company’s price sensitive statement, Square Pharma made a profit of around Tk1,900 crore in FY23, which was also the highest profit in its history, The Business Standard reported last month.

In FY23, its earnings per share (EPS) stood at Tk21.41, which was 5% higher than the previous fiscal year. Its net asset value per share grew 9% to Tk129.95 over the previous fiscal.

 

Source: The Business Standard

Facebook
LinkedIn
Shopping Basket

Iram Hoque

Mohd. Iramul Hoque (Iram) completed his bachelor’s degree in Industrial Engineering in 2018 from Purdue University.

He joined Deloitte Consulting LLP as a Consulting Analyst based out of New York City having previously worked in similar roles at PricewaterhouseCoopers LLP & Landis+Gyr.

Iram left consulting and returned to Bangladesh to take up the family business. Realizing the opportunity in the capital market in Bangladesh, Iram worked relentlessly to found Columbia Shares & Securities Ltd in 2021.

Md Saiful Hoque

Md. Saiful Hoque received his bachelor’s degree in Civil Engineering from Columbia University in 1986 followed by a master’s degree from Texas A&M University in 1988. Upon completion of his Graduate Degree, he joined Gulf Interstate Engineering Company in Houston, USA serving as a Project Engineer.

He returned to Bangladesh in 1992 to join Columbia Enterprise Ltd., the family business of Shipping and Freight Forwarding services. In addition, he has built flourishing businesses manufacturing Garment’s Accessories and Fast-Moving Consumer Goods.